Loading...
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
van Akkooi, A. C. Hauschild, A. Long, G. V. Mandala, M. Kicinski, M. Govaerts, A. S. Klauck, I. Ouali, M. Eggermont, A. M.
van Akkooi, A. C.
Hauschild, A.
Long, G. V.
Mandala, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Eggermont, A. M.
Citations
Altmetric:
Abstract
Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
van Akkooi AC, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future oncology (London, England). 2023 Sep 4. PubMed PMID: 37665297. Epub 2023/09/04. eng.